Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free ZSQR Stock Alerts

Coeptis Therapeutics (ZSQR) Competitors

Coeptis Therapeutics logo
$13.82 -0.26 (-1.85%)
As of 04:00 PM Eastern
Compare

ZSQR vs. FBRX, AGMB, IVVD, NAGE, and PBYI

Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Forte Biosciences (FBRX), AgomAb Therapeutics (AGMB), Invivyd (IVVD), Niagen Bioscience (NAGE), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

How does Coeptis Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

In the previous week, Forte Biosciences and Forte Biosciences both had 3 articles in the media. Forte Biosciences' average media sentiment score of 1.11 beat Coeptis Therapeutics' score of 0.49 indicating that Forte Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Forte Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Forte Biosciences currently has a consensus target price of $67.00, indicating a potential upside of 145.51%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forte Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Coeptis Therapeutics has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte BiosciencesN/AN/A-$69.38M-$4.77N/A
Coeptis Therapeutics$1.36M63.21-$11.92M-$2.98N/A

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Forte Biosciences has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -803.96%. Forte Biosciences' return on equity of -98.36% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Forte BiosciencesN/A -98.36% -82.81%
Coeptis Therapeutics -803.96%-110.89%-78.30%

Forte Biosciences has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.

Summary

Forte Biosciences beats Coeptis Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Coeptis Therapeutics compare to AgomAb Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for AgomAb Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.49 beat AgomAb Therapeutics' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AgomAb Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

AgomAb Therapeutics has a consensus target price of $32.00, indicating a potential upside of 156.00%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe AgomAb Therapeutics is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

AgomAb Therapeutics has lower revenue, but higher earnings than Coeptis Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coeptis Therapeutics$1.36M63.21-$11.92M-$2.98N/A
AgomAb TherapeuticsN/AN/AN/AN/AN/A

13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AgomAb Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -803.96%. AgomAb Therapeutics' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coeptis Therapeutics-803.96% -110.89% -78.30%
AgomAb Therapeutics N/A N/A N/A

Summary

AgomAb Therapeutics beats Coeptis Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Invivyd?

Coeptis Therapeutics (NASDAQ:ZSQR) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Coeptis Therapeutics' average media sentiment score of 0.49 beat Invivyd's score of 0.27 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Invivyd
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Coeptis Therapeutics has higher earnings, but lower revenue than Invivyd. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coeptis Therapeutics$1.36M63.21-$11.92M-$2.98N/A
Invivyd$53.43M7.36-$52.49M-$0.32N/A

Coeptis Therapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Invivyd has a consensus target price of $8.00, indicating a potential upside of 475.54%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Invivyd
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Invivyd has a net margin of -98.25% compared to Coeptis Therapeutics' net margin of -803.96%. Invivyd's return on equity of -48.65% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coeptis Therapeutics-803.96% -110.89% -78.30%
Invivyd -98.25%-48.65%-34.48%

Summary

Invivyd beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Niagen Bioscience?

Coeptis Therapeutics (NASDAQ:ZSQR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for Niagen Bioscience. Coeptis Therapeutics' average media sentiment score of 0.49 beat Niagen Bioscience's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Niagen Bioscience has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coeptis Therapeutics$1.36M63.21-$11.92M-$2.98N/A
Niagen Bioscience$129.42M2.98$17.38M$0.2024.10

Coeptis Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.

Niagen Bioscience has a consensus target price of $15.00, indicating a potential upside of 211.20%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Niagen Bioscience has a net margin of 13.43% compared to Coeptis Therapeutics' net margin of -803.96%. Niagen Bioscience's return on equity of 21.10% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coeptis Therapeutics-803.96% -110.89% -78.30%
Niagen Bioscience 13.43%21.10%14.92%

Summary

Niagen Bioscience beats Coeptis Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Puma Biotechnology has a net margin of 13.62% compared to Coeptis Therapeutics' net margin of -803.96%. Puma Biotechnology's return on equity of 27.80% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Puma Biotechnology13.62% 27.80% 15.35%
Coeptis Therapeutics -803.96%-110.89%-78.30%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 23.3% of Puma Biotechnology shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 2 mentions for Puma Biotechnology. Coeptis Therapeutics' average media sentiment score of 0.49 beat Puma Biotechnology's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Puma Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500.

Puma Biotechnology has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$228.37M1.64$31.11M$0.6112.05
Coeptis Therapeutics$1.36M63.21-$11.92M-$2.98N/A

Summary

Puma Biotechnology beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZSQR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZSQR vs. The Competition

Export
MetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.96M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-4.6438.8529.0428.47
Price / Sales63.21155.53476.6160.94
Price / CashN/A57.8827.6236.52
Price / Book5.257.039.676.67
Net Income-$11.92M$23.62M$3.55B$332.53M
7 Day Performance-7.99%3.67%1.70%2.01%
1 Month Performance15.36%7.16%5.62%9.20%
1 Year Performance70.62%67.03%34.42%39.59%

Coeptis Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZSQR
Coeptis Therapeutics
0.1945 of 5 stars		$13.82
-1.8%		N/AN/A$85.96M$1.36MN/A2
FBRX
Forte Biosciences
3.2025 of 5 stars		$28.03
+6.2%		$67.00
+139.0%		N/A$389.23MN/AN/A5
AGMB
AgomAb Therapeutics
N/A$10.74
+0.9%		$32.00
+198.0%		N/A$389.19MN/AN/A62
IVVD
Invivyd
2.3222 of 5 stars		$1.36
-1.4%		$8.00
+488.2%		N/A$384.61M$53.43MN/A100
NAGE
Niagen Bioscience
3.3065 of 5 stars		$4.76
-1.7%		$16.00
+236.1%		N/A$381.18M$129.42M23.80120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel